Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Risvodetinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Inhibikase Therapeutics Reports Q2 Financial Results And Recent Activity
    Inhibikase Therapeutics Reports Q2 Financial Results And Recent Activity

    14 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/14/2930514/0/en/Inhibikase-Therapeutics-Reports-Second-Quarter-Financial-Results-and-Highlights-Recent-Period-Activity.html

    GLOBENEWSWIRE
    14 Aug 2024
    Share Share
    Inhibikase Completes Enrollment Of Phase 2 Trial For Risvodetinib In Parkinson’s
    Inhibikase Completes Enrollment Of Phase 2 Trial For Risvodetinib In Parkinson’s

    17 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/17/2899626/0/en/Inhibikase-Therapeutics-Completes-Enrollment-of-the-Phase-2-201-Trial-Evaluating-Risvodetinib-in-Untreated-Parkinson-s-Disease.html

    GLOBENEWSWIRE
    17 Jun 2024
    Share Share
    Inhibikase Therapeutics to Provide Trial Update for Risvodetinib
    Inhibikase Therapeutics to Provide Trial Update for Risvodetinib

    07 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/07/2842246/0/en/Inhibikase-Therapeutics-to-Provide-Trial-Update-for-Risvodetinib-at-the-2024-International-Conference-on-Alzheimer-s-and-Parkinson-s-Diseases-and-Related-Neurological-Disorders.html

    GLOBENEWSWIRE
    07 Mar 2024
    Share Share
    Inhibikase Announces Publication Highlighting Results from Ph 1 with Risvodetinib
    Inhibikase Announces Publication Highlighting Results from Ph 1 with Risvodetinib

    29 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/01/29/2818972/0/en/Inhibikase-Therapeutics-Announces-Publication-Highlighting-Results-from-its-Phase-1-Studies-with-Risvodetinib.html

    GLOBENEWSWIRE
    29 Jan 2024
    Share Share
    Inhibikase Highlights Functional Analysis from the 201 Trial of Risvodetinib
    Inhibikase Highlights Functional Analysis from the 201 Trial of Risvodetinib

    16 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/16/2760510/0/en/Inhibikase-Therapeutics-Highlights-Unblinded-Functional-Analysis-from-the-201-Trial-of-Risvodetinib-in-Untreated-Parkinson-s-Disease-and-Provides-Update-on-Ongoing-Enrollment.html

    GLOBENEWSWIRE
    16 Oct 2023
    Share Share
    Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib
    Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib

    04 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/04/2754577/0/en/Inhibikase-Therapeutics-Receives-FDA-Orphan-Drug-Designation-for-Risvodetinib-for-the-Treatment-of-Multiple-System-Atrophy.html

    GLOBENEWSWIRE
    04 Oct 2023
    Share Share